COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

COVID-19 Evidence Alerts needs your support. If our service is of value to you, please consider donating to keep it going. Learn more Donate now

Treatment Nakhlband A, Fakhari A, Azizi H Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn Schmiedebergs Arch Pharmacol. 2021 Feb 15. pii: 10.1007/s00210-021-02061-x. doi: 10.1007/s00210-021-02061-x.
Abstract

Severe acute respiratory syndrome coronavirus 2 principally weakens the hosts' innate immune system by impairing the interferon function and production. Type I interferons (IFNs) especially IFN-ß are best known for their antiviral activities. IFNs accompanied by the standard care protocols have opened up unique opportunities for treating the coronavirus disease 2019 (COVID-19). The databases including PubMed, SCOPUS, EMBASE, and Google Scholar were searched up to October 30, 2020. The primary and secondary outcomes were considered discharge and mortality, respectively. The abovementioned outcomes of standard care protocol were compared with the standard care plus IFN-ß in the confirmed COVID-19 patients. Out of 356 records identified, 12 randomized clinical trial studies were selected for full-text screening. Finally, 5 papers were included in the systematic review and 3 papers in the meta-analysis. The average mortality rate was reported as 6.195% and 18.02% in intervention and control groups, respectively. Likewise, the median days of hospitalization were lower in the intervention group (9 days) than the control group (12.25 days). According to meta-analysis, IFN-ß was found to increase the overall discharge rate (RR = 3.05; 95% CI: 1.09-5.01). Our findings revealed that early administration of IFN-ß in combination with antiviral drugs is a promising therapeutic strategy against COVID-19.

Ratings
Discipline / Specialty Area Score
Infectious Disease
Intensivist/Critical Care
Hospital Doctor/Hospitalists
Internal Medicine
Comments from MORE raters

Hospital Doctor/Hospitalists rater

As a practicing hospitalist, I find this study demonstrates the problem with research in emerging diseases. There are multiple small poorly designed studies with heterogeneous designs and outcomes making meta-analysis difficult. Given that several of the studies had hydroxychloroquine in either the treatment or the control groups, and other antiviral agents as well, no conclusion can be drawn from the apparent tendency toward improvement. The authors also excluded studies with 'no effect'. The inclusion might have diluted the effect seen in the analysis. There were only a little more than 200 patients in the studies which severely limits the utility of meta analysis.